Scientist, Radiochemistry

Overview

Fusion Pharmaceuticals, a member of the AstraZeneca Group, is a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical portfolio includes: FPI-2265 targeting PSMA for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting IGF-1 receptor currently in a Phase 1 trial; FPI-2059, a small molecule targeting NTSR1, currently in a Phase 1 trial; and FPI-2068, a bispecific IgG-based EGFR-cMET targeted radioconjugate currently in a Phase 1 trial. In addition, Fusion is pursuing combination programs between RCs and DDR inhibitors and immune-oncology agents. Fusion has a fully operational GMP compliant radiopharmaceutical manufacturing facility to meet supply demand for Fusion’s growing pipeline of RCs.

The ...